Staying on low-dose Wegovy or Zepbound was linked to modest weight loss

What happened

People who stayed on the lowest starting doses of semaglutide (the drug in Wegovy) or tirzepatide (the drug in Zepbound) for at least six months still lost weight, as first reported by Healthline News. The loss was modest, roughly 2% to 6% of body weight at one year.

The bottom line: it is a signal worth examining, but not proof that deliberate microdosing works. It also says nothing about cost, even though cost is why many people are asking.

One caveat on our end. The paper, published Aug. 31 in Biology Methods & Protocols, was not accessible to us. Every figure below comes from Healthline's account and its quotes from the authors, so treat the numbers as provisional.

What the study reported

The researchers used electronic health records, so this is observational. It included 814 people who met the criteria for sustained low-dose semaglutide and 1,016 who met the criteria for sustained low-dose tirzepatide.

"Sustained low dose" had specific meanings. For semaglutide, it was at least three 0.25 mg doses spanning six months or more. For tirzepatide, it was 2.5 mg doses spanning at least six months.

The two semaglutide figures for low-dose users come from different analyses. The 1.7% number is from a comparison matched on age, sex, BMI and type 2 diabetes status, so don't blend them.

Co-author Venky Soundararajan, PhD, of nference, said the reductions persisted through 15 months of follow-up. He described "modest sustained weight loss in the 2-7% range," a wider range than the 2% to 6% figure cited above, which should be reconciled against the paper.

He also said, per Healthline's account and not verified against the paper, that low-dose semaglutide had lower 24-month rates of side effects than conventional doses: constipation (23.3% vs. 36.3%), nausea (39.7% vs. 50.1%) and low blood pressure (1.7% vs. 5.4%). He said low-dose tirzepatide produced modestly more weight loss, while the overall adverse-event pattern favored low-dose semaglutide.

What it does not show

• It is not a microdosing study. Healthline says the researchers did not establish that participants were intentionally microdosing. The group looks like people who stayed on the standard starting dose, by choice or not. That differs from the fractional dosing trending online.
• It cannot show cause and effect. People who remain on a low dose may differ from those who escalate. They may have had side effects, supply or insurance limits, or reached their goals. We could not verify how the paper handled this.
• The time frames differ. Weight loss is reported at one year, follow-up at 15 months and side effects at 24 months. We could not confirm which outcomes use which cohort.
• It did not measure cost or access. Nothing in Healthline's account says the study examined either. That angle is ours.
• It is not an approval. Healthline notes that using these drugs outside approved dosing schedules is not FDA- or manufacturer-approved.

An outside expert urged caution too. Mir Ali, MD, of MemorialCare, who was not involved, said many patients stop losing weight on the lowest dose and most need some escalation.

What it means for you

If you take or are considering one of these drugs, the study suggests the starting dose alone may produce some weight loss for some people. The key word is some. The matched comparison shows a large gap versus high-dose semaglutide.

For reference, Wegovy starts at 0.25 mg weekly and steps up every four weeks to a 2.4 mg maintenance dose. Zepbound starts at 2.5 mg weekly and steps up every four weeks, to as high as 15 mg.

• Don't treat this as a reason to stretch your supply or split doses on your own.
• If cost, side effects or supply are the issue, tell your prescriber. Dose pacing is a conversation to have with them.
• Be wary of any pitch that cites this study as proof that a fractional dose is as good as the labeled one.

Context: why people are asking about cost

A PMC article on microdosing tirzepatide describes it as an off-label technique using lower or fractional doses, aimed at access, affordability or tolerability. It notes that tirzepatide multi-dose pens became commercially available in the U.S. in February 2026. It also says formal guidelines do not exist and that it is not clinical guidance.

The risks sit mostly with do-it-yourself versions. Healthline's earlier reporting says microdosing requires compounded drugs that patients draw up themselves, with experts raising overdose and contamination concerns. It also says no current evidence supports the claims made for microdosing.

The FDA says unapproved or compounded GLP-1s do not go through its review for safety, effectiveness and quality. It says compounded drugs should be used only when an approved drug cannot meet a patient's medical needs.

Cleveland Clinic says there are no official microdosing guidelines and that the American Diabetes Association does not endorse it. One of its physicians does not recommend compounded versions because they are untested.

We did not find comment on this study from the manufacturers or obesity medicine societies. Until there is a trial that compares dosing strategies directly, this is a hypothesis worth testing, not a cost-saving plan.